Maveropepimut-S Emerging Drug Insight and Market Forecast - 2032

"Maveropepimut-S Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about maveropepimut-S for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the maveropepimut-S for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the maveropepimut-S for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the maveropepimut-S market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary:

Maveropepimut-S (MVP-S), (previously known as DPX-Survivac) is a DPX-based immunotherapy that delivers antigenic peptides of survivin to eliminate survivin-expressing cells by educated, cytotoxic T cells (IMV, 2022a).

Maveropepimut-S is administered with oral intermittent low-dose cyclophosphamide (CPA), which can act as an immune modulator, increasing the number of survivin-specific T cells generated without inducing significant cytotoxicity.

Currently, Maveropepimut-S is being tested in a Phase IIb (VITALIZ) trial in R/R DLBCL. Site activation and enrollment in the VITALIZE Phase IIb clinical trial increased during the third quarter of 2022. VITALIZE is designed to evaluate the clinical benefit of MVP-S in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with R/R DLBCL. Details on the VITALIZE Phase IIb study were presented as a trial-in-progress poster at the European Society for Medical Oncology 2022. The company will present clinical response data in a plenary session at the ImmunoOncology 360 (IO360) conference. IMV is on track to complete enrollment in the first study stage by H1 2023.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the maveropepimut-S description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on maveropepimut-S regulatory milestones and other development activities have been provided in this report.
• The report also highlights the maveropepimut-S research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around maveropepimut-S.
• The report contains forecasted sales of maveropepimut-S for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for maveropepimut-S in DLBCL.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Maveropepimut-S Analytical Perspective by DelveInsight

In-depth Maveropepimut-S Market Assessment

This report provides a detailed market assessment of maveropepimut-S for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

Maveropepimut-S Clinical Assessment

The report provides the clinical trials information of maveropepimut-S for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence maveropepimut-S dominance.
• Other emerging products for DLBCL are expected to give tough market competition to maveropepimut-S and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of maveropepimut-S in DLBCL.
• Our in-depth analysis of the forecasted sales data of maveropepimut-S from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the maveropepimut-S in DLBCL.

Key Questions:

• What is the product type, route of administration and mechanism of action of maveropepimut-S?
• What is the clinical trial status of the study related to maveropepimut-S in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the maveropepimut-S development?
• What are the key designations that have been granted to maveropepimut-S for DLBCL?
• What is the forecasted market scenario of maveropepimut-S for DLBCL?
• What are the forecasted sales of maveropepimut-S in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to maveropepimut-S for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?